EWTX · Insider Trading
Edgewise Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by EWTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Jonathan C Fox | Director | A | +308 | — |
| 2026-08-17 | Alan J Russell | Chief Scientific Officer | A | +65,000 deriv. | — |
| 2026-08-17 | Joanne M. Donovan | CMO | A | +65,000 deriv. | — |
| 2026-08-17 | Behrad Derakhshan | Chief Business Officer | A | +100,000 deriv. | — |
| 2026-08-17 | Michael Nofi | Chief Financial Officer | A | +48,750 deriv. | — |
| 2026-08-17 | John R Moore | General Counsel | A | +65,000 deriv. | — |
| 2026-08-14 | Michael Nofi | Chief Financial Officer | A | +73,125 deriv. | — |
| 2026-08-14 | Joanne M. Donovan | CMO | MIXED | +3,371 | −$412.70K |
| 2026-08-14 | Alan J Russell | Chief Scientific Officer | MIXED | +6,911 | −$258.04K |
| 2026-08-14 | John R Moore | General Counsel | MIXED | +7,483 | −$219.82K |
| 2026-08-14 | Kevin Koch | President and CEO | MIXED | +21,873 | −$785.04K |
| 2026-08-14 | Behrad Derakhshan | Chief Business Officer | MIXED | +8,181 | −$223.42K |
| 2026-07-17 | Jonathan D Root | Director | A | +16,377 deriv. | — |
| 2026-07-02 | Alan J Russell | Chief Scientific Officer | MIXED | — | −$7.81M |
| 2026-07-01 | Jonathan C Fox | Director | A | +319 | — |
| 2026-06-17 | Peter A. Thompson | Director | A | +16,377 deriv. | — |
| 2026-06-17 | Arlene Morris | Director | A | +16,377 deriv. | — |
| 2026-06-17 | Laura Brege | Director | A | +16,377 deriv. | — |
| 2026-06-16 | Christopher Nathan Martin | Director | A | +16,377 deriv. | — |
| 2026-06-16 | Jonathan C Fox | Director | A | +16,377 deriv. | — |
| 2026-06-16 | Badreddin Edris | Director | A | +13,807 deriv. | — |
| 2026-05-05 | Joanne M. Donovan | CMO | MIXED | −5,230 | −$1.74M |
| 2026-04-03 | Jonathan C Fox | Director | A | +339 | — |
| 2026-04-02 | Joanne M. Donovan | CMO | MIXED | — | −$723.17K |
| 2026-03-30 | Joanne M. Donovan | CMO | Sell | −16,358 | −$506.73K |
| 2026-01-23 | Badreddin Edris | Director | MIXED | — | −$3.23M |
| 2026-01-05 | Jonathan C Fox | Director | A | +473 | — |
| 2025-11-24 | Christopher Nathan Martin | Director | A | +45,150 deriv. | — |
| 2025-11-13 | Alan J Russell | Chief Scientific Officer | MIXED | — | −$2.09M |
| 2025-11-13 | Jonathan C Fox | Director | Buy | +10,700 | +$199.40K |
| 2025-11-13 | Michael Nofi | Chief Financial Officer | A | +306,250 deriv. | — |
| 2025-10-02 | Jonathan C Fox | Director | A | +728 | — |
| 2025-08-28 | Alan J Russell | Chief Scientific Officer | MIXED | — | −$1.44M |
| 2025-08-14 | Robert Blaustein | Chief Development Officer | A | +122,500 deriv. | — |
| 2025-08-14 | R Michael Carruthers | Chief Financial Officer | MIXED | +4,353 | −$19.12K |
| 2025-08-14 | Joanne M. Donovan | CMO | MIXED | +2,919 | −$38.33K |
| 2025-08-14 | Alan J Russell | Chief Scientific Officer | MIXED | +3,874 | −$25.54K |
| 2025-08-14 | Kevin Koch | President and CEO | MIXED | +9,996 | −$106.76K |
| 2025-08-14 | Behrad Derakhshan | Chief Business Officer | MIXED | +3,290 | −$33.36K |
| 2025-08-14 | John R Moore | General Counsel | MIXED | +3,683 | −$28.10K |
| 2025-07-02 | Jonathan C Fox | Director | A | +858 | — |
| 2025-06-18 | Peter A. Thompson | Director | A | +30,000 deriv. | — |
| 2025-06-18 | Laura Brege | Director | A | +30,000 deriv. | — |
| 2025-06-18 | Jonathan C Fox | Director | A | +30,000 deriv. | — |
| 2025-06-18 | Arlene Morris | Director | A | +30,000 deriv. | — |
| 2025-06-18 | Badreddin Edris | Director | A | +30,000 deriv. | — |
| 2025-06-18 | Jonathan D Root | Director | A | +30,000 deriv. | — |
| 2025-05-07 | R Michael Carruthers | Chief Financial Officer | MIXED | +3,895 | −$21.62K |
| 2025-05-07 | Joanne M. Donovan | CMO | MIXED | +5,230 | −$85.35K |
| 2025-05-07 | John R Moore | General Counsel | MIXED | +3,279 | −$31.76K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| OrbiMed Genesis GP LLC | Director | 14,809,075 | $667.00M |
| Peter A. Thompson | Director | 443,792 | $19.99M |
| Kevin Koch | President and CEO | 88,087 | $3.97M |
| R Michael Carruthers | Chief Financial Officer | 86,162 | $3.88M |
| Badreddin Edris | Director | 61,209 | $2.76M |
| Behrad Derakhshan | Chief Business Officer | 34,451 | $1.55M |
| Alan J Russell | Chief Scientific Officer | 34,129 | $1.54M |
| Jonathan C Fox | Director | 25,141 | $1.13M |
| John R Moore | General Counsel | 22,713 | $1.02M |
| Jonathan D Root | Director | 15,625 | $703.75K |
| Joanne M. Donovan | CMO | 8,625 | $388.47K |
| Marc Semigran | Chief Development Officer | 8,445 | $380.36K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EWTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.